There is on-going development of generic EU CTD Dossier of Risedronate, tablets, 5/30/35 mg.
Development of this pharmaceutical is carried out according to EU-requirements in country without patent protection or with Bolar-provisions. There will be no sales in those countries where this offer would constitute an infringement of third parties intellectual proprietary rights.
Risedronic acid (INN) or risedronate sodium (USAN, trade name Actonel) is a bisphosphonate used to strengthen bone, treat or prevent osteoporosis, and treat Paget's disease of bone.
More details at: http://www.rxlist.com/actonel-drug.htm.
|Pharma licensing||Out-licensing (offer)|